Literature DB >> 17624750

Clara cell 16 protein in COPD sputum: a marker of small airways damage?

Fulvio Braido1, Anna M Riccio, Laura Guerra, Cinzia Gamalero, Alberto Zolezzi, Francesco Tarantini, Barbara De Giovanni, Chiara Folli, Desideria Descalzi, Giorgio Walter Canonica.   

Abstract

RATIONALE: The development of chronic obstructive pulmonary disease (COPD) in smokers and their susceptibility to infections is not fully understood. Recent evidences suggest that Clara cells play a part in host defense, immunomodulatory response and airways remodelling through the production of specific factors such as Clara cell 16 (CC-16). This protein has never been related to patients' lung function tests, blood gases parameters and diseases severity.
OBJECTIVES: To evaluate a possible correlation between CC-16 expression in sputum, measured by a new methodological approach, and the degree of severity in patients with moderate and severe COPD. We also analyzed possible correlations between CC-16 and cytological sputum population, arterial blood gases and lung function. MAIN
FINDINGS: We analyzed 20 patients, mean age 72.95, classified on the basis of the global initiative for chronic obstructive lung disease guidelines (GOLD 2006). The samples were processed for cytological analysis and CC-16 levels were assessed by Western blot. We found lower levels of CC-16 in severe COPD compared to moderate ones (p<0.027). No statistically significant differences were found between CC-16 expression and sputum cellularity (except for macrophages), arterial blood gases, and spirometric parameters. Multiple linear regression analysis of CC-16 versus functional and cytological parameters showed no significance.
CONCLUSIONS: We found a significantly different expression of CC-16 in COPD patients, according to their stage of severity, as defined by the GOLD 2006 guidelines. Considering CC-16 properties in innate immunity, a possible link between protein expression, innate immune system, and COPD infectious exacerbations may be hypothesized but further investigation are needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17624750     DOI: 10.1016/j.rmed.2007.05.023

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  20 in total

1.  The Club Cell Marker SCGB1A1 Downstream of FOXA2 is Reduced in Asthma.

Authors:  Lingxiang Zhu; Lingling An; Di Ran; Rosa Lizarraga; Cheryl Bondy; Xu Zhou; Richart W Harper; Shu-Yi Liao; Yin Chen
Journal:  Am J Respir Cell Mol Biol       Date:  2019-06       Impact factor: 6.914

2.  Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study.

Authors:  Stefano Guerra; Marilyn Halonen; Monica M Vasquez; Amber Spangenberg; Debra A Stern; Wayne J Morgan; Anne L Wright; Iris Lavi; Lluïsa Tarès; Anne-Elie Carsin; Carlota Dobaño; Esther Barreiro; Jan-Paul Zock; Jesús Martínez-Moratalla; Isabel Urrutia; Jordi Sunyer; Dirk Keidel; Medea Imboden; Nicole Probst-Hensch; Jenny Hallberg; Erik Melén; Magnus Wickman; Jean Bousquet; Danielle C M Belgrave; Angela Simpson; Adnan Custovic; Josep M Antó; Fernando D Martinez
Journal:  Lancet Respir Med       Date:  2015-07-06       Impact factor: 30.700

3.  Prolidase activity dysregulation and its correlation with oxidative-antioxidative status in chronic obstructive pulmonary disease.

Authors:  Mehmet Gencer; Nurten Aksoy; E Canan Dagli; Elmas Uzer; Sahin Aksoy; Sahbettin Selek; Hakim Celik; Hale Cakir
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

Review 4.  Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease.

Authors:  Joanna L Richens; Richard A Urbanowicz; Elizabeth A M Lunt; Rebecca Metcalf; Jonathan Corne; Lucy Fairclough; Paul O'Shea
Journal:  Respir Res       Date:  2009-04-22

5.  Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease.

Authors:  Deog Kyeom Kim; Michael H Cho; Craig P Hersh; David A Lomas; Bruce E Miller; Xiangyang Kong; Per Bakke; Amund Gulsvik; Alvar Agustí; Emiel Wouters; Bartolome Celli; Harvey Coxson; Jørgen Vestbo; William MacNee; Julie C Yates; Stephen Rennard; Augusto Litonjua; Weiliang Qiu; Terri H Beaty; James D Crapo; John H Riley; Ruth Tal-Singer; Edwin K Silverman
Journal:  Am J Respir Crit Care Med       Date:  2012-11-09       Impact factor: 21.405

6.  Sputum and nasal lavage lung-specific biomarkers before and after smoking cessation.

Authors:  Izolde Bouloukaki; Ioanna G Tsiligianni; Maria Tsoumakidou; Ioanna Mitrouska; Emmanuel P Prokopakis; Irene Mavroudi; Nikolaos M Siafakas; Nikolaos Tzanakis
Journal:  BMC Pulm Med       Date:  2011-06-02       Impact factor: 3.317

7.  Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity.

Authors:  Debra A Cockayne; Donavan T Cheng; Benjamin Waschki; Sriram Sridhar; Palanikumar Ravindran; Holly Hilton; Galina Kourteva; Hans Bitter; Sreekumar G Pillai; Sudha Visvanathan; Kai-Christian Müller; Olaf Holz; Helgo Magnussen; Henrik Watz; Jay S Fine
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

8.  RNA-Seq quantification of the human small airway epithelium transcriptome.

Authors:  Neil R Hackett; Marcus W Butler; Renat Shaykhiev; Jacqueline Salit; Larsson Omberg; Juan L Rodriguez-Flores; Jason G Mezey; Yael Strulovici-Barel; Guoqing Wang; Lukas Didon; Ronald G Crystal
Journal:  BMC Genomics       Date:  2012-02-29       Impact factor: 3.969

9.  How air pollution influences clinical management of respiratory diseases. A case-crossover study in Milan.

Authors:  Pierachille Santus; Antonio Russo; Enzo Madonini; Luigi Allegra; Francesco Blasi; Stefano Centanni; Antonio Miadonna; Gianfranco Schiraldi; Sandro Amaducci
Journal:  Respir Res       Date:  2012-10-18

10.  Differential Expression Study of Lysine Crotonylation and Proteome for Chronic Obstructive Pulmonary Disease Combined with Type II Respiratory Failure.

Authors:  Qing Gan; Donge Tang; Qiang Yan; Jiejing Chen; Yong Xu; Wen Xue; Lu Xiao; Fengping Zheng; Huixuan Xu; Yingyun Fu; Yong Dai
Journal:  Can Respir J       Date:  2021-06-15       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.